Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sangamo Therapeutics (SGMO) Operating Expenses (2016 - 2025)

Sangamo Therapeutics has reported Operating Expenses over the past 16 years, most recently at $52.4 million for Q4 2025.

  • Quarterly results put Operating Expenses at $52.4 million for Q4 2025, up 56.32% from a year ago — trailing twelve months through Dec 2025 was $160.8 million (down 0.6% YoY), and the annual figure for FY2025 was $160.8 million, down 0.6%.
  • Operating Expenses for Q4 2025 was $52.4 million at Sangamo Therapeutics, up from $36.1 million in the prior quarter.
  • Over the last five years, Operating Expenses for SGMO hit a ceiling of $139.9 million in Q1 2023 and a floor of $33.5 million in Q4 2024.
  • Median Operating Expenses over the past 5 years was $70.2 million (2021), compared with a mean of $69.0 million.
  • Biggest five-year swings in Operating Expenses: soared 90.39% in 2023 and later plummeted 71.29% in 2024.
  • Sangamo Therapeutics' Operating Expenses stood at $67.9 million in 2021, then rose by 21.71% to $82.6 million in 2022, then fell by 22.42% to $64.1 million in 2023, then crashed by 47.67% to $33.5 million in 2024, then skyrocketed by 56.32% to $52.4 million in 2025.
  • The last three reported values for Operating Expenses were $52.4 million (Q4 2025), $36.1 million (Q3 2025), and $36.2 million (Q2 2025) per Business Quant data.